Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8208060 | 0.87 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL12112971 | 0.85 | MEN1 (0.72) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL16291121 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1885192 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL28569820 | 0.83 | MEN1 (0.71) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL30640703 | 0.83 | EPHX1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL2683478 | 0.83 | EPHX1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL31206342 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1878337 | 0.82 | MEN1 (0.69) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL1514839 | 0.82 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | claimed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | claimed |
| US-9517993-B2 | Antagonists of the toll-like receptor 1/2 complex | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150251987-A1 | ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-10 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009054878-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150251987-A1 | ANTAGONISTS OF THE TOLL-LIKE RECEPTOR 1/2 COMPLEX | TLR2, TLR1, TLR3 | MEN1 4848/4885KMT2A 2587/4885NPC1 3460/4885 |
| US-20110110958-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA | TP53, NUP205, ANXA5 | MEN1 2133/4885KMT2A 2664/4885NPC1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.